News for Bio-Thera Solutions,Ltd. (688177.SS)

PR NewswireGUANGZHOU, China, Feb. 7, 2025 The European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for BAT2506 as a b

PR NewswireGUANGZHOU, China, Dec. 24, 2024 GUANGZHOU, China, Dec. 24, 2024 /PRNewswire/ -- Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biophar

Bio-Thera Solutions Partners with Tabuk Pharmaceuticals to Commercialize BAT2206, a Stelara ® (Ustekinumab) Biosimilar in Saudi Arabia

PR NewswireGUANGZHOU, China, Dec. 16, 2024 GUANGZHOU, China, Dec. 16, 2024 /PRNewswire/ -- Bio-Thera Solutions, a commercial-stage biopharmaceutical compan

Japan's Food Immunomodulators market is projected to rise at a CAGR of 6.8% through 2034, the integration of advanced microbiome culture systems and...

Tumor necrosis factor inhibitor drugs industry is projected to witness a CAGR of 2.2% during the period 2024-2032. This growth can be attributed to...

Bio-Thera Solutions Receives Positive CHMP Opinion for Avzivi ® (bevacizumab), a Biosimilar Referencing Avastin ®

Bio-Thera Solutions Presents Clinical Data for BAT8006 (Folate Receptor-alpha-ADC) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK

The Psoriasis Vulgaris treatment market is expected to increase due to the increasing geriatric population across the globe. Advances in technology,...

/PRNewswire/ -- Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative assets and biosimilars,...

Newark, New Castle, USA, April 28, 2023 (GLOBE NEWSWIRE) -- According to a recent Growth Plus Reports study the Golimumab Market is expected to register...

/PRNewswire/ -- DelveInsight's 'Rheumatoid Arthritis Pipeline Insight 2022' report provides comprehensive global coverage of available, marketed, and pipeline...